|
gptkbp:instanceOf
|
gptkb:small_molecule
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:CASNumber
|
gptkb:1229705-06-9
|
|
gptkbp:clinicalTrialPhase
|
Phase 1
Phase 2
|
|
gptkbp:developedBy
|
gptkb:Roche
|
|
gptkbp:hasInChIKey
|
QJQYJZKZBOVQJZ-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C31H29Cl2F2N3O4
|
|
gptkbp:hasSMILES
|
CC1=CC(=O)N(C2=CC=CC=C12)C3=CC=C(C=C3)C4=NC5=C(C(=C(N4)Cl)Cl)C(=O)N(C5=O)C6=CC=C(C=C6)F
|
|
gptkbp:hasTargetDisease
|
gptkb:acute_myeloid_leukemia
solid tumors
hematological malignancies
|
|
gptkbp:hasUNII
|
6Z1Y2V4S2E
|
|
gptkbp:intendedUse
|
anticancer agent
|
|
gptkbp:mechanismOfAction
|
gptkb:MDM2_inhibitor
|
|
gptkbp:molecularWeight
|
632.5 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3544943
46215522
|
|
gptkbp:restoresFunctionOf
|
gptkb:p53_protein
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:status
|
investigational
|
|
gptkbp:synonym
|
gptkb:idasanutlin
gptkb:RO5503781
|
|
gptkbp:target
|
gptkb:MDM2_protein
|
|
gptkbp:therapeuticArea
|
oncology
|
|
gptkbp:bfsParent
|
gptkb:idasanutlin
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
RG7388
|